Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + toripalimab
- Development stage
- Unknown
- Lead developer
- Zai Lab
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Niraparib + toripalimab is an investigational combination therapy comprising two distinct agents with complementary mechanisms of action, evaluated primarily in oncology clinical trials. Niraparib is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP), which impairs DNA repair in cancer cells, leading to cell death—especially in tumors with homologous recombination deficiency. Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The combination aims to exploit both direct tumoricidal effects and immunomodulation for synergistic efficacy. This regimen has been studied in phase II clinical trials for metastatic, recurrent, or persistent cervical cancer[1][2][3][4].
- Other names
- niraparib + toripalimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on niraparib + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + toripalimab.